<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00849615</url>
  </required_header>
  <id_info>
    <org_study_id>S396 FLOT3</org_study_id>
    <nct_id>NCT00849615</nct_id>
  </id_info>
  <brief_title>Prospective Study With FLOT in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction</brief_title>
  <acronym>FLOT3</acronym>
  <official_title>A Prospective Multicenter Study With 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Krankenhaus Nordwest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Krankenhaus Nordwest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with locally advanced or metastatic gastric carcinoma or carcinoma of the
      esophagogastric junction without prior palliative therapy will be treated with 8 cycles of
      the FLOT scheme (up to 12 cycles if the response is favourable). Prior to enrollment a unique
      and detailed clinical evaluation of the dissemination of the disease will be done which
      includes a differentiated regard of the metastatic status. patients will be classified as
      having either (A) locally advanced, (B) limited metastatic, or (C) extensive metastatic
      disease. In arms A and B surgical intervention is planned if operability is reached. The
      hypothesis is that by classifying patients more individually by the state of their disease,
      patients in arm B will have a significantly prolonged overall survival compared to patients
      in arm C.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      250 patients with locally advanced or metastatic gastric carcinoma or carcinoma of the
      esophagogastric junction without prior palliative therapy will be treated with 8 cycles of
      the FLOT scheme (up to 12 cycles if the response is favourable). Prior to enrolment a unique
      and detailed clinical evaluation of the dissemination of the disease will be done which
      includes a differentiated regard of the M-category in the TNM classification. A prospective
      stratification will classify the patients as having either (A) locally advanced, (B) limited
      metastatic, or (C) extensive metastatic disease. In addition, the pharmacogenetic risk
      profile of the patients will be evaluated by a combined analysis of two genetic polymorphisms
      of the metabolism of the applied substances (XPD312, GSTT1). For the assessment of the
      disease, reference regions are examined by CT or MRI scans and if applicable endoscopy prior
      to the start of the study, every 2 months during and after the end of therapy until
      progression of the disease occurs. Evaluation of quality of life (by standard forms like
      EORTC-Q30 and others) is continued after progression. Clinical examinations (blood count,
      assessment of toxicity, anamnesis) is performed every two weeks for evaluation of toxicity
      and application of chemotherapy. After informed consent is given, peripheral blood of the
      patient will be analysed for the pharmacogenetic risk profile. Representative tumor material
      will be analysed by immunohistochemistry and quantitative PCR for the expression of several
      molecular factors.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>every 2 weeks during study, every 3 months follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenetic risk profile</measure>
    <time_frame>once at beginning</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>every 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) and response rate (Stratum B and C)</measure>
    <time_frame>every 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of R0-resections, rate of pathological remissions and perioperative morbidity and mortality in stratum A and B Perioperative Morbidit채t und Mortalit채t in dem Arm A und ggf. B</measure>
    <time_frame>after surgical intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">252</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Adenocarcinoma of the Esophagogastric Junction</condition>
  <arm_group>
    <arm_group_label>FLOT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>50mg/m2 qd15</description>
    <arm_group_label>FLOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>2600mg/m2 qd15</description>
    <arm_group_label>FLOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>85mg/m2 qd15</description>
    <arm_group_label>FLOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>folinic acid</intervention_name>
    <description>200mg/m2 qd15</description>
    <arm_group_label>FLOT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic or locally advanced gastric cancer or adenocarcinoma of the esophagogastric
             junction

          -  No prior chemotherapy in metastatic state

          -  Adequate blood and biochemistry parameters

        Exclusion Criteria:

          -  Hypersensitivity for 5-FU, Leucovorin, Oxaliplatin or Docetaxel

          -  KHK, cardiomyopathy or cardiac insufficiency

          -  Malignancy &lt;5 years ago

          -  Brain metastases

          -  Severe internal disease or inadequate blood and biochemistry parameters

          -  Pregnancy and lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salah Al-Batan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institute of Clinical Cancer Research IKF, UCT - University Cancer Center, Frankfurt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Krankenhaus Nordwest</name>
      <address>
        <city>Frankfurt</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, J채ger E; Arbeitsgemeinschaft Internistische Onkologie. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008 Mar 20;26(9):1435-42. doi: 10.1200/JCO.2007.13.9378.</citation>
    <PMID>18349393</PMID>
  </reference>
  <reference>
    <citation>Al-Batran SE, Hartmann JT, Hofheinz R, Homann N, Rethwisch V, Probst S, Stoehlmacher J, Clemens MR, Mahlberg R, Fritz M, Seipelt G, Sievert M, Pauligk C, Atmaca A, J채ger E. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2008 Nov;19(11):1882-7. doi: 10.1093/annonc/mdn403. Epub 2008 Jul 31.</citation>
    <PMID>18669868</PMID>
  </reference>
  <reference>
    <citation>Al-Batran SE, Atmaca A, Hegewisch-Becker S, Jaeger D, Hahnfeld S, Rummel MJ, Seipelt G, Rost A, Orth J, Knuth A, Jaeger E. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol. 2004 Feb 15;22(4):658-63.</citation>
    <PMID>14966088</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2009</study_first_submitted>
  <study_first_submitted_qc>February 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2009</study_first_posted>
  <last_update_submitted>April 5, 2016</last_update_submitted>
  <last_update_submitted_qc>April 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

